Citi analyst David Hoang raised the firm’s price target on Longboard Pharmaceuticals to $50 from $45 and keeps a Buy rating on the shares post the Q2 report. The firm is becoming increasingly comfortable with the “Other DEE” indication representing a near blockbuster opportunity for bexicaserin on its own, and potentially larger than Dravet.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard Pharmaceuticals Reports Promising LP659 Study Results
- Longboard Pharmaceuticals management to meet with Oppenheimer
- Don’t Miss Out! These 3 Stocks Are Set for Explosive Growth After Major Upgrades
- Longboard Pharmaceuticals price target raised to $60 from $36 at Baird
- Longboard Pharmaceuticals price target raised to $45 from $40 at Citi